The overarching goal of cancer immunotherapy is to drive an attack by a patient’s own immune system against tumor tissue—to destroy a tissue that the patient does not want.

Armed with the insight that successful outcomes in cancer immunotherapy rely upon mechanisms similar to those driving other forms of tissue attack by the immune system, Atreca is developing a pipeline of antibody-based therapeutics, generated via its Discovery Engine, that initiate, shape, and extend the anti-tumor immune response in cancer patients via multiple mechanisms.

Atreca’s portfolio of antibody therapeutics drives tumor-targeting by the immune system in multiple indications, in large subgroups of patients, as monotherapy, and in combination with other agents.

Let's Connect

Please contact us to learn more about Atreca.